Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TauRx Therapeutics’ experimental Alzheimer's drug LMTX has failed to meet its co-primary endpoints in a phase 3 clinical trial.
Subscribe to our email newsletter
The company said treatment with its tau aggregation inhibitor had a marked beneficial effect on key measures of Alzheimer's disease in patients with mild or moderate forms of the disease.
LMTX as monotherapy showed significant reductions in disease progression in mild and moderate Alzheimer's disease.
The same efficacy findings were however not demonstrated in study patients who took LMTX in combination with other standard Alzheimer's treatments.
The clinical trial, dubbed TRx-237-015, was conducted on 891 patients with mild or moderate Alzheimer's disease that compared treatment for 15 months with LMTX with placebo.
Initial analysis from second phase 3 study in patients with mild Alzheimer's disease confirmed positive findings.
TauRx co-founder Claude Wischik said: "The results we have seen in this study confirm the results we saw in our Phase 2 study, where an earlier version of the drug was also given as monotherapy.
“The results we see in those patients not taking Alzheimer's disease medications show the considerable potential of LMTX as a monotherapy for both mild and moderate Alzheimer's disease.
“Perhaps more importantly, these results support the targeting of the tau tangle pathology in Alzheimer's disease as being a very promising drug development pathway. However, the reason for the observed loss of efficacy of LMTX when taken in combination with currently available treatments for Alzheimer's disease is not as yet understood."